Skip to main content
. 2020 Aug 27;54:37–45. doi: 10.1016/j.breast.2020.08.008

Table 1.

Baseline clinical characteristics of study participants.

Study groups
P-value
CRS (n = 41) CRP (n = 39) Control (n = 41)

Mean ± SD
Mean ± SD
Mean ± SD

Age (years) 53.80 ± 1.42 52.41 ± 1.19 53.24 ± 1.5 0.736a
Physical activity (MET-minutes/week) 369.42 ± 194.37 342.24 ± 187.45 426.19 ± 234.40 0.182a
Time since cancer treatment (years) 5.43 ± 1.09 3.34 ± 3.7 3.66 ± 7.5 0.401a
Tumor size (cm) 3.19 ± 03 3.24 ± 0.34 2.65 ± 0.19 0.527a
CDT course numbers
15.66 ± 0.5
15.09 ± 0.5
14.24 ± 0.5
0.207a

Number (%)
Number (%)
Number (%)

Chemotherapy 39 (%95.1) 37 (%94.9) 40 (%97.6) 0.847b
Radiotherapy 41 (%100) 35 (%89.7) 34 (%82.9) 0.026b
Homogeneity of hands 19 (%46.3) 22 (%56.4) 21 (%51.2) 0.566b
Lymphedema stage 0.690b
I 6 (%14.6) 8 (%20.5) 7 (%17.1)
II 35 (%85.4) 31 (%79.5) 33 (%80.5)
Surgery type 0.331b
Mastectomy 26 (%63.4) 26 (%66.7) 20 (%48.8)
Lumpectomy 15 (%36.6) 13 (%33.3) 21 (%51.2)
Breast cancer stage at diagnosis 0.616b
I 3 (%7.3) 4 (%10.3) 1 (%2.4)
II 32 (%78) 28 (%71.8) 31 (%75.6)
III 6 (%14.6) 7 (%17.9) 9 (%22)
Estrogen status 0.700b
Positive 30 (%73.2) 31 (%79.5) 31 (%75.6)
Negative 11 (%26.8) 8 (%20.5) 10 (%24.4)
Progesterone status 0.648b
Positive 31 (%75.6) 27 (%69.2) 28 (%68.3)
Negative 10 (%24.4) 12 (%30.8) 13 (%31.7)
HER2 status 0.752b
Positive 9 (%22) 7 (%17.9) 6 (%14.6)
Negative 32 (%78) 32 (%82.1) 35 (%85.6)

Note: CRS group refers to the subjects received a calorie-restricted diet plus synbiotic, while CRP group followed a calorie-restricted diet plus placebo.

Abbreviations SD, standard deviation; MET, metabolic equivalent; CDT, complete decongestive therapy; HER2, human epidermal growth factor receptor 2.

a

Obtained from one-way ANOVA.

b

Obtained from Chi-square or Fisher exact test.